461 related articles for article (PubMed ID: 32817336)
1. Chemistry of Class 1 CRISPR-Cas effectors: Binding, editing, and regulation.
Liu TY; Doudna JA
J Biol Chem; 2020 Oct; 295(42):14473-14487. PubMed ID: 32817336
[TBL] [Abstract][Full Text] [Related]
2. Unity among the diverse RNA-guided CRISPR-Cas interference mechanisms.
Ganguly C; Rostami S; Long K; Aribam SD; Rajan R
J Biol Chem; 2024 Jun; 300(6):107295. PubMed ID: 38641067
[TBL] [Abstract][Full Text] [Related]
3. Fanzor is a eukaryotic programmable RNA-guided endonuclease.
Saito M; Xu P; Faure G; Maguire S; Kannan S; Altae-Tran H; Vo S; Desimone A; Macrae RK; Zhang F
Nature; 2023 Aug; 620(7974):660-668. PubMed ID: 37380027
[TBL] [Abstract][Full Text] [Related]
4. Inhibition Mechanism of an Anti-CRISPR Suppressor AcrIIA4 Targeting SpyCas9.
Yang H; Patel DJ
Mol Cell; 2017 Jul; 67(1):117-127.e5. PubMed ID: 28602637
[TBL] [Abstract][Full Text] [Related]
5. Identification of RNA Binding Partners of CRISPR-Cas Proteins in Prokaryotes Using RIP-Seq.
Sharma S; Sharma CM
Methods Mol Biol; 2022; 2404():111-133. PubMed ID: 34694606
[TBL] [Abstract][Full Text] [Related]
6. Type III CRISPR-Cas Systems: Deciphering the Most Complex Prokaryotic Immune System.
Kolesnik MV; Fedorova I; Karneyeva KA; Artamonova DN; Severinov KV
Biochemistry (Mosc); 2021 Oct; 86(10):1301-1314. PubMed ID: 34903162
[TBL] [Abstract][Full Text] [Related]
7. Assembly of Francisella novicida Cpf1 endonuclease in complex with guide RNA and target DNA.
Alcón P; Montoya G; Stella S
Acta Crystallogr F Struct Biol Commun; 2017 Jul; 73(Pt 7):409-415. PubMed ID: 28695850
[TBL] [Abstract][Full Text] [Related]
8. Molecular Mechanisms of RNA Targeting by Cas13-containing Type VI CRISPR-Cas Systems.
O'Connell MR
J Mol Biol; 2019 Jan; 431(1):66-87. PubMed ID: 29940185
[TBL] [Abstract][Full Text] [Related]
9. [Advances in the RNA-targeting CRISPR-Cas systems].
Hong T; Luo Q
Sheng Wu Gong Cheng Xue Bao; 2023 Apr; 39(4):1363-1373. PubMed ID: 37154311
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Diverse CRISPR-Cas Systems and Expansion of the Genome Engineering Toolbox.
Koonin EV; Gootenberg JS; Abudayyeh OO
Biochemistry; 2023 Dec; 62(24):3465-3487. PubMed ID: 37192099
[TBL] [Abstract][Full Text] [Related]
11. Regulation of cyclic oligoadenylate synthesis by the
Nasef M; Muffly MC; Beckman AB; Rowe SJ; Walker FC; Hatoum-Aslan A; Dunkle JA
RNA; 2019 Aug; 25(8):948-962. PubMed ID: 31076459
[TBL] [Abstract][Full Text] [Related]
12. Characterization and applications of Type I CRISPR-Cas systems.
Hidalgo-Cantabrana C; Barrangou R
Biochem Soc Trans; 2020 Feb; 48(1):15-23. PubMed ID: 31922192
[TBL] [Abstract][Full Text] [Related]
13. Characterization and Repurposing of Type I and Type II CRISPR-Cas Systems in Bacteria.
Hidalgo-Cantabrana C; Goh YJ; Barrangou R
J Mol Biol; 2019 Jan; 431(1):21-33. PubMed ID: 30261168
[TBL] [Abstract][Full Text] [Related]
14. Shooting the messenger: RNA-targetting CRISPR-Cas systems.
Zhu Y; Klompe SE; Vlot M; van der Oost J; Staals RHJ
Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29748239
[TBL] [Abstract][Full Text] [Related]
15. The CRISPR-associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA.
Fonfara I; Richter H; Bratovič M; Le Rhun A; Charpentier E
Nature; 2016 Apr; 532(7600):517-21. PubMed ID: 27096362
[TBL] [Abstract][Full Text] [Related]
16. Structure of the miniature type V-F CRISPR-Cas effector enzyme.
Takeda SN; Nakagawa R; Okazaki S; Hirano H; Kobayashi K; Kusakizako T; Nishizawa T; Yamashita K; Nishimasu H; Nureki O
Mol Cell; 2021 Feb; 81(3):558-570.e3. PubMed ID: 33333018
[TBL] [Abstract][Full Text] [Related]
17. Guide RNAs: A Glimpse at the Sequences that Drive CRISPR-Cas Systems.
Briner AE; Barrangou R
Cold Spring Harb Protoc; 2016 Jul; 2016(7):. PubMed ID: 27371605
[TBL] [Abstract][Full Text] [Related]
18. Functional Features and Current Applications of the RNA-Targeting Type VI CRISPR-Cas Systems.
Perčulija V; Lin J; Zhang B; Ouyang S
Adv Sci (Weinh); 2021 Jul; 8(13):2004685. PubMed ID: 34254038
[TBL] [Abstract][Full Text] [Related]
19. Insights Gained from RNA Editing Targeted by the CRISPR-Cas13 Family.
Liu L; Pei DS
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232699
[TBL] [Abstract][Full Text] [Related]
20. Anti-CRISPRs: Protein Inhibitors of CRISPR-Cas Systems.
Davidson AR; Lu WT; Stanley SY; Wang J; Mejdani M; Trost CN; Hicks BT; Lee J; Sontheimer EJ
Annu Rev Biochem; 2020 Jun; 89():309-332. PubMed ID: 32186918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
